Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 17/20 | 0.82 |
| ▸ | DRD2 | P14416 | 16/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7552763 | 0.90 | DRD4 (1.00) | DRD4DRD2MEN1ADRA1DADRA1A | |
| SCHEMBL7553491 | 0.88 | DRD2 (0.83) | DRD4DRD2MEN1ADRA1DADRA1A | |
| SCHEMBL7551427 | 0.88 | DRD2 (0.83) | DRD4DRD2SMN1; SMN2MEN1ADRA1D | |
| SCHEMBL7558681 | 0.87 | DRD4 (0.81) | DRD4DRD2MEN1ADRA1DADRA1A | |
| SCHEMBL7555333 | 0.85 | DRD2 (0.78) | DRD4DRD2HTTMEN1ADRA1D | |
| SCHEMBL7555846 | 0.84 | DRD2 (0.77) | DRD4DRD2MEN1ADRA1DADRA1A | |
| SCHEMBL8208943 | 0.77 | DRD2 (0.65) | DRD4DRD2NOTUM | |
| SCHEMBL7557175 | 0.74 | DRD2 (0.81) | DRD4DRD2MEN1ADRA1DADRA1A | |
| SCHEMBL23551256 | 0.74 | ALDH1A1 (0.67) | DRD4DRD2ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL18291967 | 0.73 | ALDH1A1 (0.65) | DRD4DRD2ALDH1A1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020128274-A1 | Benzylpiperazinyl-indolinylethanones | NEUROGEN CORPORATION. | 2002-09-12 | — | — | US | claimed |
| WO-2000076967-A1 | BENZYLPIPERAZINYL-INDOLINYLETHANONES | NEUROGEN CORPORATION (US) | 2000-12-21 | — | — | WO | claimed |
| US-20020128274-A1 | Benzylpiperazinyl-indolinylethanones | NEUROGEN CORPORATION. | 2002-09-12 | — | — | US | disclosed |
| US-6355644-B1 | NERVOUS SYSTEM DISORDERS AND TREATMENT OF SCHIZOPHRENIA AND BIPOLAR DISORDER | NEUROGEN CORPORATION | 2002-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128274-A1 | Benzylpiperazinyl-indolinylethanones | GABRP, GABBR1, GABARAP | DRD4 57/4885DRD2 30/4885ALDH1A1 445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.